These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33284790)

  • 1. Absence of nuclear receptors LXRs impairs immune response to androgen deprivation and leads to prostate neoplasia.
    Bousset L; Septier A; Bunay J; Voisin A; Guiton R; Damon-Soubeyrant C; Renaud Y; De Haze A; Sapin V; Fogli A; Rambur A; De Joussineau C; Kocer A; Trousson A; Henry-Berger J; Höring M; Liebisch G; Matysik S; Lobaccaro JA; Morel L; Baron S
    PLoS Biol; 2020 Dec; 18(12):e3000948. PubMed ID: 33284790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors.
    Bousset L; Rambur A; Fouache A; Bunay J; Morel L; Lobaccaro JA; Baron S; Trousson A; de Joussineau C
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LXRs, SHP, and FXR in Prostate Cancer: Enemies or
    Cariello M; Ducheix S; Maqdasy S; Baron S; Moschetta A; Lobaccaro JA
    Nucl Recept Signal; 2018; 15():1550762918801070. PubMed ID: 30718981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
    Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.
    Simons BW; Durham NM; Bruno TC; Grosso JF; Schaeffer AJ; Ross AE; Hurley PJ; Berman DM; Drake CG; Thumbikat P; Schaeffer EM
    J Pathol; 2015 Feb; 235(3):478-89. PubMed ID: 25348195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of immune cells in prostate cancer.
    Wang C; Zhang Y; Gao WQ
    Cancer Lett; 2022 Jan; 525():9-21. PubMed ID: 34715253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
    Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
    J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
    Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
    Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
    Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
    Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.
    Ammirante M; Luo JL; Grivennikov S; Nedospasov S; Karin M
    Nature; 2010 Mar; 464(7286):302-5. PubMed ID: 20220849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
    Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
    Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
    Nishiyama T
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Naito S
    Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
    Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
    BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
    Liu Q; Tong D; Liu G; Gao J; Wang LA; Xu J; Yang X; Xie Q; Huang Y; Pang J; Wang L; He Y; Zhang D; Ma Q; Lan W; Jiang J
    Clin Cancer Res; 2018 Nov; 24(22):5622-5634. PubMed ID: 30012567
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.